Combination regimens with anti-CD20 agents might improve the outcomes of patients with relapsed or refractory B-cell malignancies; however, the available comparative clinical evidence is limited. The present review assessed the reported evidence on the efficacy of anti-CD20 monoclonal antibodies combined with chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL), using a rapid evidence assessment approach. MEDLINE, Embase, and the Cochrane Library were searched from January 1, 1997 to July 14, 2017 (English language only). The data identified from randomized controlled trials or single-arm prospective studies are reported as descriptive study summaries, grouped by anti-CD20 agent and outcome (overall response rate, including complete response and partial response; duration of response; survival, including overall survival and progression-free survival). Of 56 included reports, 32 reported on CLL/small lymphocytic lymphoma, 15 on FL, and 11 on DLBCL. Within the study period, 40, 11, and 7 studies evaluated rituximab, ofatumumab, and obinutuzumab, respectively. Substantially more data were available for rituximab-based combination regimens than for either ofatumumab or obinutuzumab. Moreover, substantial heterogeneity was recorded in the study design and backbone chemotherapy. Thus, the available data are inconclusive regarding any potential similarities or differences in efficacy among these anti-CD20 agents for each respective disease. More importantly, only 1 direct comparison among the anti-CD20 agents was identified, emphasizing the need for head-to-head randomized controlled trials of these drugs to inform clinical decision-making for patients with relapsed or refractory B-cell lymphoproliferative disorders.
Introduction
Non-Hodgkin lymphoma (NHL) accounts for w4.3% of all cancers in the United States. 1, 2 According to the US estimates for 2016, the number of new cases and deaths from NHL was predicted to reach 72,580, and 20,150, respectively. 1,3 Approximately 85% of cases of NHL in adults are of B-cell origin. 4, 5 The most common B-cell subtypes are diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), which account for w33% and w20%, respectively, of all lymphoma cases in the United States. 6 B-cell chronic lymphocytic leukemia (CLL) accounted for w30% of all new cases of leukemia in the United States 3 in 2016. 3, 7 CLL and 1 small lymphocytic lymphoma (SLL) are regarded as synonymous, although SLL primarily involves the lymph nodes and lacks a leukemic component. 8 Most B-cell lymphoma patients will be in their late 60s at the diagnosis. The median age at diagnosis for NHL is 67 years, 9 and the median age of those with CLL is 72 years. 10 The observation that B-cell malignancies consistently express the surface antigen CD20 led to the development of targeted therapies.
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Rituximab (Rituxan, Genentech, San Francisco, CA; MabThera, Roche, Basel, Switzerland) is a chimeric monoclonal antibody (mAb) directed against CD20 (type I) that exerts antitumor effects on B cells through various mechanisms, including antibodydependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct apoptosis. [11] [12] [13] [14] Rituximab was approved by the US Food and Drug Administration (FDA) in 1997 for the treatment of relapsed or refractory CD20 þ NHL. 11, 15 Rituximab was approved in 1998 by the European Commission for the treatment of relapsed or chemoresistant grade 3/4 FL. 16 Data from pivotal phase II [17] [18] [19] [20] and phase III trials [21] [22] [23] [24] led to the approval of rituximab as combination therapy for the treatment of DLBCL, CLL, FL, and other advanced NHLs. [25] [26] [27] Although rituximab combination treatment is effective against CD20 þ lymphoproliferative disorders, [28] [29] [30] resistance to second-or third-line treatment is common. 15, [31] [32] [33] [34] Attempts to improve the antitumor activity of anti-CD20 mAbs have led to the development of second-and third-generation anti-CD20 agents. 29, 35, 36 Ofatumumab, a second-generation, fully human, type I anti-CD20 mAb, recognizes a different epitope than rituximab, has binding affinity for both the large and the small extracellular domains of CD20, and has a slower dissociation rate than that of rituximab. 37 Positive results from early trials 38, 39 led to accelerated FDA approval of ofatumumab for CLL in 2009 and conditional marketing authorization by the European Medicines Agency in 2010 for the treatment of patients with CLL refractory to fludarabine and alemtuzumab. 37, 40 Ofatumumab has also been approved in the United States for extended treatment of recurrent or progressive CLL. 41 Obinutuzumab is a third-generation, humanized, type II anti-CD20 mAb that binds to the protein epitope on the CD20 channel, which partially overlaps the region recognized by rituximab. 42 Compared with rituximab, obinutuzumab exerts greater antibody-dependent cellular cytotoxicity and direct B-cell apoptotic effects but has less of an effect on complement-dependent cytotoxicity. 43 Obinutuzumab was first approved by the FDA in 2013 and by the European Union in 2014 as a first-line treatment of CLL [43] [44] [45] [46] and has been approved for the treatment of patients with relapsed/refractory FL. 47, 48 Treating refractory or relapsed B-cell neoplasms represents a clinical challenge, 49, 50 especially for patients with so-called rituximab-refractory disease (ie, a lack of response to, or progression within 6 months of, a rituximab-containing regimen). Also, limited evidence is available regarding the comparative efficacy of different anti-CD20 agents combined with chemotherapy. To address this question, we collated and summarized the available reported evidence on the efficacy of rituximab-, ofatumumab-, and obinutuzumab-containing treatment regimens for patients with relapsed or refractory disease with the most common B-cell lymphoproliferative disorders: CLL, FL, and DLBCL.
Materials and Methods

Search Strategy
An rapid evidence assessment (REA) 51 was conducted using the OVIDSP interface (Ovid Technologies, Inc, Norwood, MA) to search MEDLINE/Medline in process and Embase from January 1, 1997 to July 14, 2017 to identify full-text reports or congress abstracts. The Cochrane Library was also searched for the same period.
Text word or MeSH headings containing the interventions of interest (ie, "rituximab," "Rituxan," "MabThera," "obinutuzumab," "Gazyva," "Gazyvaro," "GA101," "ofatumumab," "Arzerra," "HuMax-CD20") were used. The specific disease and study design terms used included "lymphoma," "non-Hodgkin lymphoma," "B cell lymphoma," "follicular lymphoma," "diffuse large B cell lymphoma," "chronic lymphocytic leukemia," "subopt$," "refract$," "relaps$," "random*," "blind," "clinical trial," "cohort," and "crossover." The final search results from each database were limited to human studies reported in English. The reference lists of the relevant systematic and narrative reviews were searched manually to capture additional studies not retrieved by the database searches.
Eligibility Criteria
Only randomized controlled trials (RCTs) or single-arm prospective studies that had enrolled patients with relapsed or refractory CLL and/or SLL, DLBCL, or FL were included in the present analysis, regardless of the disease stage or treatment history. The anti-CD20 mAb interventions of interest were rituximab, ofatumumab, and obinutuzumab combined with the following regimens: bendamustine, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) , CVP (cyclophosphamide, vincristine, prednisolone), dexamethasone, fludarabine, FC (fludarabine, cyclophosphamide), FM (fludarabine, mitoxantrone), FCM (fludarabine, cyclophosphamide, mitoxantrone), chlorambucil, ICE (ifosfamide, carboplatin, etoposide), DHAP (dexamethasone, highdose cytarabine, cisplatin), ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin), EPOCH (etoposide, prednisolone, vincristine, cyclophosphamide, hydroxydaunorubicin, doxorubicin), ibrutinib, idelalisib, and venetoclax. To better understand the available evidence regarding the efficacy of these complex regimens, which have been shown to demonstrate preferable response rates compared with anti-CD20 monotherapy, we focused on combination therapy. Therefore, monotherapy studies for rituximab, ofatumumab, and obinutuzumab were excluded. Also, studies reported after the search cutoff date (July 14, 2017) were not included in the present review.
Quality Assessment
Because the present analysis was an REA, 2 complementary checklist approaches were used, as described by Preston et al, 62 to assess study quality in lieu of a validated risk of bias tool. The relevant quality parameters included single versus multicenter study site, 1 intervention versus more interventions or conditions investigated, data collection methods, and statistical adjustment for the baseline population. The evaluation of study quality was informed by the limitations reported in the included studies and the study design. The quality assessment was undertaken by the same reviewers who had extracted the data, and disagreements were resolved by a senior researcher.
Results
Literature Search
Of the 4242 citations identified from the databases and manual searches of the relevant reviews, a high-level screen of 3638 nonduplicate titles and abstracts was performed, with 236 reports meeting the criteria for full-text screening. After the full-text screening, 180 were excluded from the final analysis for the following reasons: the intervention, study type, patient population, or outcomes did not meet the eligibility criteria; the outcomes of interest were not reported; or a full-text report was available for a corresponding abstract publication (ie, the same study). After this final screening step, 46 studies from 56 reports met the study inclusion criteria (Supplemental Table 2 ; available in the online version).
Of the 56 included publications, 37 were full-text articles and 19 were conference abstracts, 2 of which had reported interim data. 63, 64 Of the 56 reports, 31 (19 reports 2, [83] [84] [85] ). Of the 56 publications, 40 evaluated rituximab, 2, 23, [52] [53] [54] [55] [56] [63] [64] [65] [66] [67] [68] 70, 71, [74] [75] [76] [77] [78] 82 -100 11 investigated ofatumumab, 2, 69, 72, 73, [101] [102] [103] [104] [105] [106] and 7 evaluated obinutuzumab. [79] [80] [81] [107] [108] [109] [110] Two publications evaluated both ofatumumab and rituximab. 2 At the time of the present analysis, no reported data were identified for anti-CD20 mAbs combined with venetoclax or EPOCH for patients with relapsed or refractory CLL, FL, or DLBCL.
The included studies differed considerably owing to multiple factors, including study population, comparators, follow-up period, assessments, and outcomes; therefore, the study results were not directly compared. Descriptive summaries, grouped by outcome and by anti-CD20 agent, are presented to provide a qualitative overview of the key findings of each report.
Overall Response Rate
The ORRs stratified by intervention and median age are shown in Figure 1 for patients with relapsed or refractory CLL, FL, or DLBCL. Detailed information for each study is provided in Supplemental Tables 3-5 (available in the online version). Of the 3 agents, rituximab was evaluated in more studies, with the ORR reported in more rituximab combination regimens (32 studies 2, 23, [52] [53] [54] [55] 63, 65, 66, 68, 71, [75] [76] [77] [78] [83] [84] [85] [86] [87] [88] [89] [90] [92] [93] [94] [95] [96] [97] 100, 105, 111 ) than either ofatumumab (8 studies 2, 69, 73, [101] [102] [103] [104] [105] [106] or obinutuzumab (5 studies 79-81,107-110 ).
Chronic Lymphocytic Leukemia. The reported ORR and CR data for patients with CLL were both available for 11 different rituximab-combination regimens, 63, [65] [66] [67] [68] 71, 76, [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] with the most data reported for rituximab /FC. 65, 71, 86, 91, 93, 94 Most of the identified data on rituximab therapy combinations were for populations with a median age < 65 years 65, 66, 71, 76, 86, 88, [91] [92] [93] [94] (Supplemental   Table 3 ; available in the online version). The ORR was available for 4 different ofatumumab combinations from 6 studies, 69,72,73,101- Follicular Lymphoma. The ORR and CR data for FL were retrieved from 10 studies for 8 different rituximab-combination regimens. 23, [52] [53] [54] [55] [56] 77, 78, 94, 100 Most of the available data included patient groups with a median age of < 65 years. Figure 1B ; Supplemental Table 4 ; available in the online version). 
Anti-CD20 Antibody Regimens for CLL, DLBCL, and FL
Diffuse Large B-cell Lymphoma. Five different rituximabcontaining regimens from 8 studies had ORR and CR data available for the treatment of DLBCL (Supplemental Table 5 ; available in the online version). 83, 85, [95] [96] [97] 99 The ORRs obtained from studies investigating rituximab, bendamustine in patients with a median age of ! 65 years ranged from 45.8% (95% CI, 41.0%-70.0%) 99 to 62.7% (95% CI, 49.1%-75.0%; Figure 1C ). 97 In 1 rituximab study, the intent-to-treat population included candidates poorly suited for aggressive therapy, which could have affected the reported ORR.
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The ORR ( Figure 1C ) and CR data, all of which included patient populations with a median age of < 65 years, were identified for ofatumumab combined with DHAP or ICE (2 studies). 2, 106 No studies of obinutuzumab for relapsed or refractory DLBCL patients were identified in the present analysis.
DOR, PFS, and OS
The DOR, PFS, and OS time-to-event data and rates at specified follow-up times are presented in Tables 1-3 for CLL, FL, and DLBCL, respectively. The PFS data across all 3 diseases have been reported for more combination regimens with rituximab (n ¼ 22) than with either ofatumumab (n ¼ 8) or obinutuzumab (n ¼ 1). Although more studies had included rituximab, fewer studies overall had reported the DOR (rituximab, n ¼ 6; ofatumumab, n ¼ 1;
Chronic Lymphocytic Leukemia. The DOR, PFS, and OS outcomes from studies of patients with relapsed or refractory CLL are presented in Table 1 . DOR data were available for 4 rituximabcombination regimens across 6 studies. 65, 71, 74, 76, 88, 89 Only 1 study reported data for patients with a median age of ! 65 years.
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No CLL studies reporting the DOR from either ofatumumab-or obinutuzumab-combination therapy were identified. PFS data from the studies of CLL were available for 7 different rituximab-containing regimens. [65] [66] [67] [68] 71, 76, 86, 88, 89, 94 The studies reporting PFS for other rituximab combinations have been summarized in Table 1 . 66, 68, 76, 82 PFS data were available for 4 different ofatumumab combinations in 6 studies (Table 1) . 69, 73, [101] [102] [103] 105 OS data were reported for 6 different rituximab combinations in 10 studies. [64] [65] [66] [67] [68] 70, 71, 75, 76, 86, 88, 89, 93, 94 OS was not reached in a number of studies investigating rituximab-combination therapy. Two studies reported the only OS rates at different or various time points (Table 1) . 88 OS data were available for 4 different ofatumumab combinations. 69, 73, 101, 102, 105 No studies were identified that reported OS from obinutuzumab-combination therapy.
Follicular Lymphoma. Analysis of the DOR, PFS, and OS outcomes from the studies of relapsed or refractory FL revealed only 1 study investigating DOR in FL. That study reported a rate of 44% (95% CI, 27%-60%) at 36 months for patients who had received rituximab combined with FM (Table 2) . 53 PFS data in FL were available for 7 different rituximab combinations in 7 studies (Table 2) . 23, [52] [53] [54] 77, 82, 94 Across the studied combinations, the median PFS ranged from 17.75 months (95% CI, 14.66 to not reached) 52 to 54.5 months (95% CI, 23.0 to not reached).
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The OS rates were reported for patients with FL receiving 5 different rituximab combinations in 5 studies (Table 2) . 23, 53, 54, 77, 94 The median OS was not reached in 3 of these studies 53,54,77 and was not reported in the other studies. 22, 52, 55, 56, 78, 82, 97, 100 No OS data were reported for either ofatumumab or obinutuzumab in combination with any other included agent.
Diffuse Large B-cell Lymphoma. The DOR, PFS, and OS outcomes data from studies of relapsed or refractory DLBCL patients showed that only 1 study had evaluated DOR among DLBCL patients (Table 3) . 99 That study reported a median DOR of 17.3 months (95% CI, 4.2 to not reached) for patients with a median age of ! 65 years who had received rituximab, bendamustine. PFS data for patients with DLBCL were available for 4 different rituximab combinations in 6 studies. 2, 83, 84, [95] [96] [97] [98] [99] One study 2 defined PFS as the time from randomization to stable disease after cycle 2, progressive disease, or death (whichever came first). Also, only one third of patients had received autologous stem cell transplantation, which could have affected the results. The PFS endpoints were identified for ofatumumab in 2 studies. 2, 106 One RCT evaluated both rituximab and ofatumumab in combination with DHAP and reported PFS rates of 26% and 24% at 24 months. 2 Together, these findings substantiate the view that in the anti-CD20 refractory setting, outcomes will be largely influenced by the choice of backbone chemotherapy regimen, irrespective of which anti-CD20 agent is used.
OS was reported for 3 different rituximab combinations across 6 studies (Table 3) . 2, 83, 84, 95, 96, 98, 99 The median OS was not reached in 2 rituximab studies, 96,99 reportedly because of censoring. 99 OS data were reported in 2 ofatumumab studies 2, 106 ; however, the OS was not reached in patients who had received ofatumumab combined with ICE. 106 In the ofatumumab plus DHAP study, the reported OS rate was 41% (95% CI, not reported) at 24 months, respectively.
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For all 3 anti-CD20 agents, the reported evidence on MRD was insufficient to include this endpoint in the present analysis.
Discussion
Most reported efficacy outcomes meeting the study inclusion criteria were for treatment with rituximab-combination therapies, reflecting the earlier approval of this agent (1997) compared with that of ofatumumab (2009) and obinutuzumab (2013). Thus, the efficacy data reported for ofatumumab and obinutuzumab were determined from the limited evidence to date, which had been reported within a relatively short period.
Owing to the substantial heterogeneity in study design, the available data are insufficient for a comparison of the efficacy of rituximab, ofatumumab, and obinutuzumab as treatment of CLL, FL, and DBLCL. In addition, the results from several studies should be interpreted with caution owing to early termination or low patient enrollment. A study of ofatumumab plus bendamustine in patients with CLL was terminated early because of unexpected adverse events, including infusion-related reactions, infections, and neurotoxicity.
In the present analysis, the study populations were divided for ease of interpretation as "median age < 65 years" and "median age ! 65 years." In general, no correlations could be drawn between patient age and the efficacy outcomes. In the studies in which efficacy data were assessed by age group 53, 66, 86, 97, 101, 103 (with 3 different age categories), it was not possible to definitively assess the efficacy outcomes by age and thus this remains a knowledge gap. Although originally a study objective, after a review of the reported data, the MRD was omitted from our analysis owing to the paucity of studies (n ¼ 9; all of CLL) comparing the findings across diseases or treatment regimens. More information is needed to understand MRD in different indications for anti-CD20 agents.
Low response rates and limited duration of efficacy of anti-CD20 monotherapy compared with combination therapy have been reported, especially in the relapsed/refractory disease setting. Rituximab monotherapy for lymphoma led to a 47% response rate that was comparable to single-agent cytotoxic chemotherapy. 15 However, combination therapy that included rituximab led to greater response rates (eg, 79% for rituximab plus FCM 77 and 96% for rituximab plus CHOP 22 ). In addition, rituximab monotherapy had a limited (eg, median 12 months for FL) duration of efficacy. 20 To better understand the available evidence regarding the efficacy of these complex regimens, which have been shown to demonstrate preferable response rates compared with anti-CD20 monotherapy, the present review focused on combination therapy. The present analysis had several limitations. Although REAs use objective, a priori study inclusion criteria and are useful for synthesizing the latest evidence in a more timely manner than systematic literature reviews (SLRs), the methodology is less rigorous. Therefore, REAs could be subject to a relatively greater degree of bias and/or error than SLRs. 51 For example, in the present REA, reports from outside the PubMed, Embase, and Cochrane databases were not reviewed, quality assessments of the included studies were not performed with a verified risk of bias tool, and the data extraction process, although focusing on specific research questions, was less rigorous than that for traditional SLRs. However, the present REA used an objective and consistent method to searching the reported data, screening against inclusion criteria and reporting the identified data. The present review did not account for interstudy variation of factors such as the population size, treatment history, performance status (eg, Eastern Cooperative Oncology Group score), number and type of comorbidities, study duration and/or follow-up time, Anti-CD20 Antibody Regimens for CLL, DLBCL, and FL and other clinical or biologic prognostic factors. Therefore, it was not possible to provide direct comparisons among the studies or across the interventions. Another important confounder was the discrepancy between the results of the intent-to-treat and per-protocol populations. For instance, in lymphoma studies, only patients with chemosensitive disease can access curative procedures, such as autologous stem cell transplantation. Therefore, studies that only report a per-protocol analysis might have artificially better results. RCTs, in which most or all of these variables are controlled, will provide more robust evidence of the comparative efficacy of various anti-CD20-based therapies in patients with relapsed or refractory B-cell lymphoproliferative disorders. In addition, some studies reported the overall median PFS or OS in months and others reported the percentage of subjects alive or without progression at varying time points, which further hampered comparison of these endpoints across the studies.
Because the outcomes were reported as described in the source study, their definitions were not standardized in the present analysis. For example, some study investigators might have used the original response criteria for malignant lymphoma 59 and others, the 1996 National Cancer Institute-Sponsored Working Group guidelines for CLL 57 in their evaluations. It is unclear whether all studies reported details of the adopted assessment criteria or provided definitions, especially among the identified abstract publications. Although single-agent anti-CD20 therapy is often used in the relapsed or refractory setting, the present analysis excluded anti-CD20 monotherapy studies to reduce the heterogeneity among comparison groups. Finally, as with any review, our analysis only included publications available during the study search period (up to July 14, 2017) . Therefore, publications dated after the study inclusion period were not included in the present analysis. For example, 1 study, although captured in our review as an abstract publication, 2 was later reported as a full-text article and showed comparable efficacy between ofatumumab and rituximab in combination with DHAP as salvage treatment of relapsed or refractory DLBCL.
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Limited conclusions can be gleaned from the data presented by our review. In the data we have presented, the ORR appeared to be greater for obinutuzumab than for rituximab or ofatumumab. However, caution is needed for this interpretation owing to the very low numbers of studies from which the obinutuzumab data were taken. The duration of response was generally > 15 months for rituximab combination therapy for CLL and FL. However, insufficient data were reported in the ofatumumab or obinutuzumab studies to draw conclusions about the DOR. PFS was > 15 months for most rituximab combination therapies, >13 months for ofatumumab combination therapies, and 13 months in the only data point for obinutuzumab combination therapy for CLL. All these results should be interpreted carefully owing to the paucity of data available. Head-to-head comparative randomized clinical trials are needed for conclusive interpretation of efficacy differences between anti-CD20 monoclonal antibodies.
Conclusion
More than 40 studies in the present REA described a variety of anti-CD20 combination therapies used for the treatment of CLL, FL, or DLBCL. The studies identified in the present review were highly heterogeneous in design. Therefore, no conclusions could be made regarding the relative effectiveness of rituximab, ofatumumab, and obinutuzumab. Further analyses and additional data on ofatumumab-and obinutuzumab-containing regimens are required to better assess their relative effectiveness. More importantly, RCTs Anti-CD20 Antibody Regimens for CLL, DLBCL, and FL Supplemental 
